ILMN Stock Summary and Trading Ideas (Illumina | NASDAQ:ILMN)

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina trades on the NASDAQ stock market under the symbol ILMN.

As of May 15, 2026, ILMN stock price declined to $142.54 with 1,591,751 million shares trading.

ILMN has a beta of 1.73, meaning it tends to be more sensitive to market movements. ILMN has a correlation of 0.20 to the broad based SPY ETF.

ILMN has a market cap of $21.79 billion. This is considered a Large Cap stock.

Last quarter Illumina reported $1 billion in Revenue and $1.15 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.10.

In the last 3 years, ILMN traded as high as $213.91 and as low as $68.70.

The top ETF exchange traded funds that ILMN belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.

ILMN has outperformed the market in the last year with a price return of +76.2% while the SPY ETF gained +26.4%. ILMN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.0% and +5.0%, respectively, while the SPY returned +8.7% and +2.6%, respectively.

ILMN support price is $139.00 and resistance is $147.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ILMN shares will trade within this expected range on the day.